Sangamo Therapeutics (SGMO) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 5, 2022 4:01 PM EDTConference Call and Webcast Scheduled for 4:30 p.m. Eastern Time
BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.
This quarter, we have continued to progress multiple programs through clinical development and demonstrated, once again, Sangamos track record of advancing groundbreaking therapies in genomic medicine, said Sandy Macrae, Chief Executive Officer of Sangamo. We dosed a total of five patients across three programs, including the first patient in our study for the... More
